Post-treatment control of viraemia after discontinuation of antiretroviral therapy begun during primary HIV-1 infection is considered a potential path toward a sustained remission of infection.
Methods
Subjects enrolled in an observational primary infection cohort who received at least 11 months of highly active antiretroviral therapy beginning within the first 12 weeks of HIV-1 infection and who subsequently discontinued therapy were evaluated for post-treatment control.
Results
Within a cohort of 389 subjects with primary HIV-1 infection enrolled over 22 years, only 22 met criteria for evaluation of post-treatment control. Among these subjects, 21 (95%) had loss of viral control (HIV-1 RNA>500 copies/ml) within 18 months after treatment discontinuation, and only 1 (4.5%, 95% CI 0.32, 18.9) controlled viral load to levels <500 copies/ml for at least 24 months. The median time to virological failure was 2.17 (IQR 1.18–3.39) months.
Conclusions
Our data suggest a low likelihood of post-treatment control even when highly active antiretroviral therapy is started within 12 weeks of HIV-1 infection.
References
1.
Sáez-CiriónA., BacchusC., HocquelouxL.Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study.PLoS Pathog2013; 9: e1003211.
2.
KaslowR.A., CarringtonM., AppleR.Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection.Nat Med1996; 2: 405–411.
3.
MiguelesS.A., SabbaghianM.S., ShupertW.L.HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors.Proc Natl Acad Sci U S A2000; 97: 2709–2714.
4.
SchackerT., CollierA.C., HughesJ., SheaT., CoreyL.Clinical and epidemiologic features of primary HIV infection.Ann Intern Med1996; 125: 257–264.
5.
SchackerT.W., HughesJ.P., SheaT., CoombsR.W., CoreyL.Biological and virologic characteristics of primary HIV infection.Ann Intern Med1998; 128: 613–620.
6.
SteklerJ.D., WellmanR., HolteS.Are there benefits to starting antiretroviral therapy during primary HIV infection? Conclusions from the Seattle Primary Infection Cohort vary by control group.Int J STD AIDS2012; 23: 201–206.
7.
CarringtonM., O'BrienS.J.The influence of HLA genotype on AIDS.Annu Rev Med2003; 54: 535–551.
8.
ItescuS., Mathur-WaghU., SkovronM.L.HLA-B35 is associated with accelerated progression to AIDS.J Acquir Immune Defic Syndr1992; 5: 37–45.
9.
FiebigE.W., WrightD.J., RawalB.D.Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection.AIDS2003; 17: 1871–1879.
10.
RosenbergE.S., GrahamB.S., ChanE.S.Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/ early HIV-1 infection.PLoS ONE2010; 5: e10555.
11.
DaveyR.T.Jr., BhatN., YoderC.HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression.Proc Natl Acad Sci U S A1999; 96: 15109–15114.
12.
LiJ.Analysis of analytic treatment interruption in past ACTG studies. Symposium II, Intensely monitored antiretroviral pause. Annual ACTG Network Meeting. 23–24 June 2014. Washington, DC, USA.
13.
RosenbergE.S., AltfeldM., PoonS.H.Immune control of HIV-1 after early treatment of acute infection.Nature2000; 407: 523–526.
14.
Ngo-Giang-HuongN., DeveauC., Da SilvaI.Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy.AIDS2001; 15: 665–673.
15.
LodiS., MeyerL., KelleherA.D.Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion.Arch Intern Med2012; 172: 1252–1255.
16.
WilliamsJ.P., HurstJ., StohrW.HIV-1 DNA predicts disease progression and post-treatment virological control.eLIFE2014; 3: e03821.
17.
AnanworanichJ., SchuetzA., VandergeetenC.Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection.PLoS ONE2012; 7: e33948.
18.
Scott-AlgaraD., DidierC., ArnoldV.Post-treatment controllers have particular NK cells with high anti-HIV capacity: VISCONTI study.Conference on Retroviruses and Opportunistic Infections. 23–26 February 2015, Seattle, WA, USA. Abstract 52.
